Table 1.
Participant demographics and relevant baseline data for the primary study cohort (with Patient Health Questionnaire-9 outcomes available up to 12-months postintervention).
| Demographics and baseline data | All participants | Completed 8-week outcomes | Completed 6-month outcomes | Completed 12-month outcomes | Did not complete 8-week outcomes | Did not complete 6-month outcomes | Did not complete 12-month outcomes | |
| Total participants, n (%) | 102 (100) | 83 (81.4) | 44 (43.1) | 52 (51) | 19 (18.6) | 58 (56.9) | 50 (49) | |
| Age in years, mean (SD) | 32.9 (10.3) | 33.2 (10.4) | 33.5 (11.0) | 31.3 (11.0) | 31.9 (10.0) | 32.5 (9.9) | 34.6 (9.4) | |
| Gender, n (%) | ||||||||
| Male | 23 (22.5) | 19 (22.9) | 11 (25) | 10 (19.2) | 4 (21.0) | 12 (20.7) | 13 (26) | |
| Female | 79 (77.5) | 64 (77.1) | 33 (75) | 42 (80.8) | 15 (79.0) | 46 (79.3) | 37 (74) | |
| Antidepressants, n (%) | ||||||||
| Yes | 25 (24.5) | 18 (21.7) | 7 (15.9) | 7 (13.5) | 7 (36.8) | 18 (31.0) | 18 (36) | |
| No | 44 (43.1) | 37(44.6) | 24 (54.6) | 22 (42.3) | 7 (36.8) | 20 (34.5) | 22 (44) | |
| Unknown | 33 (32.4) | 28 (33.7) | 13 (29.6) | 23 (44.2) | 5 (26.3) | 20 (34.5) | 10 (20) | |
| Country, n (%) | ||||||||
| Finland | 80 (78.4) | 67 (80.7) | 36 (81.8) | 48 (92.0) | 13 (68.0) | 44 (75.9) | 32 (64.0) | |
| Unites States | 22 (21.6) | 16 (19.3) | 8 (18.2) | 4 (8.0) | 6 (32.0) | 14 (24.1) | 18 (36.0) | |
| Baseline PHQ-9a score, mean (SD)b | 12.8 (5.2) | 13.0 (5.4) | 13.2 (5.8) | 14.3 (5.0) | 11.6 (4.6) | 12.5 (4.8) | 11.2 (5.0) | |
aPHQ-9: Patient Health Questionnaire-9.
bSignificantly associated with the presence of PHQ-9 scores at the 12-month follow-up.